SOS1 inhibition enhances efficacy of KRAS G12C inhibitors in lung adenocarcinoma models
Jan. 30, 2025
KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with overall response rates ranging between 34% and 43%.